Iridex CORP 8-K filings

Iridex Corporation reconvened its Annual Meeting on July 10, 2026, addressing director elections, auditor ratification, and executive compensation, while also detailing a significant governance dispute involving a director and a major shareholder.

IRIDEX Corporation has adjourned its 2026 annual meeting of stockholders to July 10, 2026, with no changes to the proposals for voting.

Iridex Corporation announced its first quarter 2026 financial results, reporting $11.8 million in revenue and reaffirming its full-year 2026 guidance.

Iridex Corporation announced strong fourth quarter and full year 2025 financial results, driven by revenue growth and significant operating expense reductions.

IRIDEX Corporation has entered into a new 90-month triple net lease for approximately 30,784 square feet of office, R&D, and manufacturing space in San Jose, California, with an anticipated July 1, 2026 commencement.

Iridex Corporation announced preliminary unaudited operational and financial results for Q4 and full year 2025, showing continued revenue growth and positive cash flow.

IRIDEX Corporation announced its participation in the Sidoti Year-End Virtual Investor Conference on December 11, 2025, where it will present to investors.

Iridex Corporation announced an 8% year-over-year revenue increase to $12.5 million for Q3 2025, driven by strong Cyclo G6 and Retina product sales, alongside reduced operating expenses.

Iridex Corporation announced it has received formal notification from Nasdaq confirming compliance with continued listing requirements, resolving a previous non-compliance notice.

Iridex Corporation announced its second quarter 2025 financial results, reporting revenue growth and achieving positive non-GAAP adjusted EBITDA for the third consecutive quarter.

IRIDEX Corporation's stockholders have approved a significant increase in authorized common stock and an expansion of the company's equity incentive plan, alongside the re-election of directors and ratification of auditors.

IRIDEX Corporation amended its Investor Rights Agreement with Novel Inspiration International Co., Ltd., now requiring unanimous board approval for the sale of a substantial portion of the company's assets.

IRIDEX Corporation received a notification from Nasdaq regarding non-compliance with the minimum stockholders' equity requirement for continued listing.

Iridex Corporation announces its Q1 2025 financial results, highlighting revenue growth, reduced operating expenses, and a strategic investment.

Iridex Corporation announces preliminary unaudited operational and financial results for Q1 2025, projecting revenue between $11.8 million and $12.0 million.

Kenneth E. Ludlum resigns from Iridex Corporation's Board of Directors, effective April 7, 2025, as part of an agreement with Novel Inspiration International Co., Ltd.

Robert E. Grove resigns from Iridex Corporation's Board of Directors, effective April 2, 2025, as part of an agreement with Novel Inspiration International Co., Ltd.

Iridex Corporation announces positive adjusted EBITDA for the fourth quarter of 2024 and a strategic investment of $10 million, signaling improved financial health.

IRIDEX Corporation announces a strategic investment of $10 million, with a potential for an additional $10 million, along with the appointment of a new CFO and board members.

Iridex Corporation released preliminary unaudited financial results for Q4 and full year 2024, showing mixed performance and ongoing strategic review.

Iridex Corporation filed an amended 8-K report to correct the resignation date of former CEO David Bruce and provide additional details regarding his separation agreement.

IRIDEX Corporation has appointed its current President, CEO, and COO, Patrick Mercer, to its Board of Directors, effective immediately.

Iridex Corporation has announced the termination of its CEO, Dave Bruce, and has entered into a separation agreement with him, while also adjusting the compensation and severance agreement for its new CEO, Patrick Mercer.

Iridex Corporation reported a revenue decline in Q3 2024 but anticipates achieving EBITDA breakeven in Q4 due to cost-cutting measures and improved profitability.

Iridex Corporation has appointed Patrick Mercer as its new CEO, effective October 1, 2024, as part of a leadership change aimed at accelerating a strategic review process.

IRIDEX Corporation filed a resale registration statement to cover potential share issuances related to a recent financing agreement with Lind Global Asset Management IX LLC.

Iridex Corporation announced its second quarter 2024 financial results, showing revenue growth and a recent $3.4 million capital raise, while also continuing its strategic review process.

Iridex Corporation has entered into a securities purchase agreement for a convertible note financing with Lind Global Asset Management, potentially raising up to $5 million.

IRIDEX Corporation is transferring its stock listing from the Nasdaq Global Market to the Nasdaq Capital Market after failing to meet the minimum market value requirement.

IRIDEX Corporation held its 2024 Annual Meeting, electing directors, ratifying the auditor, and approving executive compensation.